NRAS and colorectal carcinoma: A large American database with 13,336 advanced CRC patients, reported a prevalence of 51.9% (n = 6926) of KRAS mutation, 4.5% (n = 594) of NRAS mutation, and 3.3% (n = 455) of MSI-high [27].